Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pulmonx closes $65mm oversubscribed Series G financing

Executive Summary

Pulmonary device maker Pulmonx Corp. raised $65mm in an oversubscribed Series G financing round led by Ally Bridge Group, which adds a board member and was joined by other first-time backers RTW Investments, ArrowMark Partners, and Driehaus Capital Management, and returning shareholders. Pulmonx has developed Zephyr Valve, which is the first FDA-approved minimally invasive device for treating severe emphysema. The company will use the funds for commercialization activities.
Deal Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies